Regular, consistent physical activity just might help reduce the symptoms of certain urological health issues, including urinary incontinence and erectile problems.

High-intensity focused ultrasound, or HIFU, is an innovative, non-invasive treatment for a wide range of tumors and diseases and has been used for prostate cancer for over 20 years. HIFU uses an ultrasound transducer, similar to the ones used for diagnostic imaging, but with much higher energy.

There is an abundance of evidence that the human microbiome plays an important and nuanced role in controlling human health, including metabolism, immunity, pain, psychological state, and cancer.

The role of genetic testing for prostate cancer risk is a rapidly changing area. Experts debate the indications of sending a patient on to genetic counseling for further potential screening for inherited prostate cancer risk. One major issue that needs to be addressed in the urology community today is recognizing the frequency of inherited mutations that are affecting prostate cancer patients.

Latest prostate cancer research is turning its focus on the M0 space. Many therapeutic options for castration-resistant prostate cancer are approved and used for metastatic castration-resistant prostate cancer (mCRPC), but fewer options exist for those with non-metastatic (NM) CRPC.

The role of imaging is paramount in this evolution by providing physicians with accurate information on both the presence and extent of prostate cancers. Developments in molecular imaging are paving the way for more physicians to diagnose cancer and apply relevant therapy.

One of the major treatments for prostate cancer is androgen-deprivation therapy (ADT), and about 50% of prostate cancer patients are treated with ADT at some point in their disease. ADT is used most frequently for patients with local but advanced prostate cancer or metastatic prostate cancer.

Nocturia is arguably the most bothersome lower urinary tract symptom and necessarily imposes a considerable burden on quality of life. The often-multifactorial etiologies contributing to nocturia obscure the establishment of a reliable diagnosis.

Upper tract urothelial carcinoma (UTUC) is cancer of the transitional urothelial cells that line the upper urothelial tract of the renal pelvis and ureter. This type of cancer accounts for between 5% and 10% of urothelial cancer cases.

These lectures were presented during the 30th Annual International Prostate Cancer Update on January 23, 2020, in Avon, Colorado.

In a GRU exclusive, Laurence Klotz, MD, FRCSC, Professor of Surgery and holder of the Sunnybrook Chair of Prostate Cancer Research at the University of Toronto, gives three Platinum Lectures on the current state of active surveillance for prostate cancer.

These lectures were presented during the 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, presented over four successive weeks throughout October, 2020.

These lectures were presented during the Perspectives in Urology Point • Counterpoint Virtual Conference on November 11, 2020.